DE69619132T2 - Chimäre oligomere mit einer rns-spaltungsaktivität - Google Patents
Chimäre oligomere mit einer rns-spaltungsaktivitätInfo
- Publication number
- DE69619132T2 DE69619132T2 DE69619132T DE69619132T DE69619132T2 DE 69619132 T2 DE69619132 T2 DE 69619132T2 DE 69619132 T DE69619132 T DE 69619132T DE 69619132 T DE69619132 T DE 69619132T DE 69619132 T2 DE69619132 T2 DE 69619132T2
- Authority
- DE
- Germany
- Prior art keywords
- oligomers
- chimeral
- rns
- rna
- cleaving activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69619132T DE69619132T2 (de) | 1995-11-14 | 1996-11-14 | Chimäre oligomere mit einer rns-spaltungsaktivität |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995142404 DE19542404A1 (de) | 1995-11-14 | 1995-11-14 | Chimäre Oligomere mit RNA-Spaltungsaktivität |
US61229896A | 1996-03-07 | 1996-03-07 | |
DE69619132T DE69619132T2 (de) | 1995-11-14 | 1996-11-14 | Chimäre oligomere mit einer rns-spaltungsaktivität |
PCT/EP1996/005014 WO1997018312A1 (en) | 1995-11-14 | 1996-11-14 | Chimeric oligomers having an rna-cleavage activity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69619132D1 DE69619132D1 (de) | 2002-03-21 |
DE69619132T2 true DE69619132T2 (de) | 2002-07-18 |
Family
ID=26020354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69619132T Expired - Fee Related DE69619132T2 (de) | 1995-11-14 | 1996-11-14 | Chimäre oligomere mit einer rns-spaltungsaktivität |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0866865B1 (de) |
JP (1) | JP2000501284A (de) |
AT (1) | ATE213019T1 (de) |
AU (1) | AU7572096A (de) |
CA (1) | CA2237528A1 (de) |
DE (1) | DE69619132T2 (de) |
WO (1) | WO1997018312A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103890A (en) * | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
US6610478B1 (en) | 1996-08-16 | 2003-08-26 | Yale University | Phenotypic conversion of cells mediated by external guide sequences |
US6300483B1 (en) | 1997-06-19 | 2001-10-09 | Ribozyme Pharmaceuticals, Inc. | Compositions inducing cleavage of RNA motifs |
JP2002510207A (ja) * | 1997-06-19 | 2002-04-02 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | 拡張された開裂ルールを有するハンマーヘッドリボザイム |
US6410225B1 (en) | 1997-06-27 | 2002-06-25 | Yale University | Purification of oligomers |
US20030165888A1 (en) | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
US6013447A (en) * | 1997-11-21 | 2000-01-11 | Innovir Laboratories, Inc. | Random intracellular method for obtaining optimally active nucleic acid molecules |
US6248525B1 (en) | 1998-03-30 | 2001-06-19 | Yale University | Method for identifying essential or functional genes |
US6902888B1 (en) | 1999-05-21 | 2005-06-07 | Myriad Genetics, Inc. | Diabetes gene |
WO2000071751A1 (en) * | 1999-05-21 | 2000-11-30 | Myriad Genetics, Inc. | Diabetes gene |
DE60025391D1 (de) * | 1999-10-26 | 2006-03-30 | Immusol Inc | Ribozym-therapie zur behandlung von proliferativen augenkranheiten |
WO2002030465A2 (en) | 2000-10-12 | 2002-04-18 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP1572168B1 (de) | 2002-02-06 | 2010-05-26 | Vicor Technologies, Inc. | Anti-infarkt-moleküle |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (de) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | Durch rna-interferenz vermittelte inhibierung von map-kinase-genen |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP2116604A1 (de) | 2002-08-05 | 2009-11-11 | University of Rochester | Proteinumwandlungsdomäne / Deaminasechimäre Proteine, zugehörige Verbindungen und Verwendungen davon |
US8658377B2 (en) | 2002-11-15 | 2014-02-25 | Morehouse School Of Medicine | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies |
US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
JP5562521B2 (ja) | 2005-02-02 | 2014-07-30 | ザ ユーエービー リサーチ ファンデーション | アポトーシス誘導デスレセプターアゴニストに対する抵抗性を低減することに関する薬剤及び方法 |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
AU2006304321B2 (en) | 2005-10-14 | 2012-10-04 | Musc Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP2560001B1 (de) | 2006-09-21 | 2016-04-13 | University of Rochester | Zusammensetzungen und Verfahren für eine Proteinverlagerungstherapie für myotone Dystrophie |
WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
US9896511B2 (en) | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
WO2010070380A2 (en) | 2007-12-03 | 2010-06-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | Doc1 compositions and methods for treating cancer |
EP2288922B1 (de) | 2008-05-08 | 2016-08-17 | University of Utah Research Foundation | Sensorische rezeptoren für chronische müdigkeit und schmerzen und verwendungen dafür |
EP2370080A1 (de) | 2008-12-02 | 2011-10-05 | University of Utah Research Foundation | Pde1 als zieltherapeutikum bei herzkrankheiten |
WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
KR20140104344A (ko) | 2011-05-20 | 2014-08-28 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 | T 세포 매개성 질병의 병증을 개선하기 위한 tl1a-dr3의 상호작용의 차단 및 그것의 항체 |
US10723794B2 (en) | 2015-03-18 | 2020-07-28 | University Of South Carolina | Anti-CcL8 antibodies and uses thereof |
CN110087665A (zh) | 2016-08-03 | 2019-08-02 | H·李·莫菲特癌症中心与研究所公司 | Tlr9靶向治疗 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE150789T1 (de) * | 1990-06-19 | 1997-04-15 | Gene Shears Pty Ltd | Endonukleasen |
CA2093664C (en) * | 1990-10-12 | 2003-07-29 | Fritz Eckstein | Modified ribozymes |
US5652094A (en) * | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
IL107480A0 (en) * | 1992-11-03 | 1994-02-27 | Gene Shears Pty Ltd | Tnf-x ribozymes and degradation resistant mrna derivatives linked to tnf-x ribozymes |
GB9225427D0 (en) * | 1992-12-04 | 1993-01-27 | Ribonetics Gmbh | Oligonucleotides with rna cleavage activity |
US5861288A (en) * | 1993-10-18 | 1999-01-19 | Ribozyme Pharmaceuticals, Inc. | Catalytic DNA |
-
1996
- 1996-11-14 JP JP9518590A patent/JP2000501284A/ja active Pending
- 1996-11-14 EP EP96938213A patent/EP0866865B1/de not_active Expired - Lifetime
- 1996-11-14 WO PCT/EP1996/005014 patent/WO1997018312A1/en active IP Right Grant
- 1996-11-14 DE DE69619132T patent/DE69619132T2/de not_active Expired - Fee Related
- 1996-11-14 AU AU75720/96A patent/AU7572096A/en not_active Abandoned
- 1996-11-14 AT AT96938213T patent/ATE213019T1/de not_active IP Right Cessation
- 1996-11-14 CA CA002237528A patent/CA2237528A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0866865A1 (de) | 1998-09-30 |
WO1997018312A1 (en) | 1997-05-22 |
AU7572096A (en) | 1997-06-05 |
JP2000501284A (ja) | 2000-02-08 |
EP0866865B1 (de) | 2002-02-06 |
ATE213019T1 (de) | 2002-02-15 |
DE69619132D1 (de) | 2002-03-21 |
CA2237528A1 (en) | 1997-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69619132T2 (de) | Chimäre oligomere mit einer rns-spaltungsaktivität | |
DK0691980T3 (da) | 7-deazapurinmodifiderende oligonukleotider | |
FI951612A (fi) | Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia | |
CA2145664A1 (en) | Oligonucleotides having a conserved g4 core sequence | |
DE69433626D1 (de) | N-2 substituierte purine | |
WO1996019568A3 (en) | Stabilized ribozyme analogs | |
ATE280772T1 (de) | Antisense oligonukleotidmodulation der raf genexpression | |
ATE239090T1 (de) | Methode zum generieren von einzelsträngigen dna molekülen | |
ATE121416T1 (de) | Oligonukleotid-analoge. | |
FR2724934B1 (fr) | Oligonucleotide chimere et son utilisation dans l'obtention de transcrits d'un acide nucleique | |
ES2193144T3 (es) | Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa. | |
EP1123414A4 (de) | Antisense modulation der expression von integrin alpha 4 | |
WO2000029623A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
DE3787998T2 (de) | ART-Nukleotidsegmente, -Vektoren, -Zellinien, Verfahren zur Herstellung und Verwendung. | |
DE69308531D1 (de) | Cycloisomaltooligosaccharide; Enzym und Verfahren zu ihrer Herstellung, und Verfahren zur Herstellung von dem Enzym | |
DK0840802T3 (da) | Fremgangsmåde til sekvensering gennem oligomerhybridisering | |
DE3778158D1 (de) | Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants. | |
WO2000029622A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8339 | Ceased/non-payment of the annual fee |